Campbell David Alan
Transaction: 07/31/2026
SELL
Change
-123,840
Price
Not reported
Filing
07/31/2026
Type
SELL
Janux Therapeutics, Inc.
JANX • Biotechnology
$20.24
▲ +0.44 (+2.22%)
Current price
EarningsLatest report: Jun 30, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$1.27B
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Positive revenue growth · 16.3%Manageable debt level · 0.02Healthy liquidity · 39.04Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 7, 2026, 1:15 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$20.24
Change2.22%
Shares Out62.94M
Market Cap$1.27B
Enterprise Value$323.93M
52W Range12.12 - 35.34
Beta2.51
P/E-12.42
P/S39.96
P/B1.37
P/FCF-23.36
EV/Sales10.16
Price$20.24
Change2.22%
Shares Out62.94M
Market Cap$1.27B
Enterprise Value$323.93M
52W Range12.12 - 35.34
Beta2.51
P/E-12.42
P/S39.96
P/B1.37
P/FCF-23.36
EV/Sales10.16
EV/EBITDA-2.92
EV/FCF-5.94
Earnings Yield-8.05%
FCF Yield-4.28%
Dividend Yield0.00%
Gross Margin79.71%
Oper. Margin-15.77%
Profit Margin-11.36%
Debt/Eq0.02
Current Ratio39.04
Quick Ratio39.04
Target$28.25
Target Upside39.58%
Target Median$24.50
Target Range14.00 - 55.00
Volume489.70K
Avg Volume1.06M
EPS Surprise0.13
Investment DNA
How strong this company looks for long-term investors
49
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
58/100
Why this score▼
Positive revenue growth · 16.3%Manageable debt level · 0.02Healthy liquidity · 39.04Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 16 analyst votes · 2026-09-05
84/100
Bullish
Bullish
12
Hold
3
Bearish
1
Price Target
2026-06-24
Low
$14.00
Mean
$23.40
Median
$22.00
High
$36.00
Insider Transactions
Recent executive and insider activity
⚠ 1 high-volume insider sell detected
Campbell David Alan
Transaction: 07/08/2026
BUY
Change
+7,000
Price
$4.21
Filing
07/10/2026
Type
BUY
Campbell David Alan
Transaction: 07/08/2026
SELL
Change
-7,000
Price
$4.21
Filing
07/10/2026
Type
SELL
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Campbell David Alan | SELL | -123,840 | Not reported | 07/31/2026 | 07/31/2026 |
| Campbell David Alan | BUY | +7,000 | $4.21 | 07/08/2026 | 07/10/2026 |
| Campbell David Alan | SELL | -7,000 | $4.21 | 07/08/2026 | 07/10/2026 |
| Barrett Ronald W | BUY | +5,500 | Not reported | 06/11/2026 | 06/12/2026 |
| Barrett Ronald W | BUY | +15,500 | $13.66 | 06/11/2026 | 06/12/2026 |
| CAPPS VICKIE L | BUY | +15,500 | $13.66 | 06/11/2026 | 06/12/2026 |
| CAPPS VICKIE L | BUY | +5,500 | Not reported | 06/11/2026 | 06/12/2026 |
| DOBMEIER ERIC | BUY | +5,500 | Not reported | 06/11/2026 | 06/12/2026 |
| DOBMEIER ERIC | BUY | +15,500 | $13.66 | 06/11/2026 | 06/12/2026 |
| Hernday Natasha | BUY | +5,500 | Not reported | 06/11/2026 | 06/12/2026 |
| Hernday Natasha | BUY | +15,500 | $13.66 | 06/11/2026 | 06/12/2026 |
| Kung Winston | BUY | +5,500 | Not reported | 06/11/2026 | 06/12/2026 |
| Kung Winston | BUY | +15,500 | $13.66 | 06/11/2026 | 06/12/2026 |
| Simson Jake | BUY | +5,500 | Not reported | 06/11/2026 | 06/12/2026 |
| Simson Jake | BUY | +15,500 | $13.66 | 06/11/2026 | 06/12/2026 |
| RA CAPITAL MANAGEMENT, L.P. | BUY | +5,500 | Not reported | 06/11/2026 | 06/12/2026 |
| RA CAPITAL MANAGEMENT, L.P. | BUY | +15,500 | $13.66 | 06/11/2026 | 06/12/2026 |
| Doyle Janeen Noel | SELL | -4,059 | $14.03 | 06/02/2026 | 06/04/2026 |
| Dobek Maria | SELL | -2,038 | $14.17 | 05/11/2026 | 05/13/2026 |
| Go William | BUY | +44,000 | Not reported | 02/02/2026 | 02/04/2026 |